{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BOVNF"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BOVNF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BOVNF\",,,,,undefined,":{"symbol":"BOVNF","market":"US","secType":"STK","nameCN":"Bioinvent International AB","latestPrice":4.7,"timestamp":1746820800000,"preClose":4.7,"halted":0,"volume":0,"delay":15,"floatShares":32815306,"shares":65804362,"eps":-0.475308,"marketStatus":"Market Closed","change":0,"latestTime":"05-09 16:00:00 EDT Delay","open":4.7,"high":4.7,"low":4.7,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.475308,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":4.7,"volumeRatio":0.014880954595380146},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BOVNF\",,,,,undefined,":{"symbol":"BOVNF","floatShares":32815306,"roa":"-24.65%","roe":"-39.11%","lyrEps":-0.499403,"volumeRatio":0.014880954595380146,"shares":65804362,"dividePrice":0,"high":4.7,"amplitude":0,"preClose":4.7,"low":4.7,"week52Low":4.7,"pbRate":"3.40","psRate":"67.42","week52High":4.7,"institutionHeld":0,"latestPrice":4.7,"eps":-0.475308,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.475308,"open":4.7,"prevYearClose":4.7,"prevWeekClose":4.7,"prevMonthClose":4.7,"prevQuarterClose":4.7,"fiveDayClose":4.7,"twentyDayClose":4.7,"sixtyDayClose":4.7},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BOVNF\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BOVNF\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531768662","title":"Resolutions at BioInvent's Annual General Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531768662","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531768662?lang=en_us&edition=fundamental","pubTime":"2025-04-29 23:15","pubTimestamp":1745939700,"startTime":"0","endTime":"0","summary":"LUND, SWEDEN / ACCESS Newswire / April 29, 2025 / The Annual General Meeting  of BioInvent International AB   resolved to re-elect the Board members Natalie Berner, Kristoffer Bissessar, Thomas Hecht, Leonard Kruimer, Laura Lassouw-Polman, Nanna Lüneborg, Vincent Ossipow and Bernd Seizinger and to implement a long-term incentive program.The AGM voted in favor of adopting the income statements and balance sheets for the Group and the parent company for the financial year 2024 and decided that no dividend should be declared for the financial year 2024.The AGM resolved to adopt the Board's report regarding compensation pursuant to Chapter 8, Section 53 a of the Swedish Companies Act.Last, the AGM authorized the Board to resolve on the issue of new shares, on one or several occasions during the period up to the ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/resolutions-bioinvents-annual-general-meeting-151500582.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BOVNF","BK4139"],"gpt_icon":0},{"id":"2531557200","title":"BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2531557200","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531557200?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:15","pubTimestamp":1745921700,"startTime":"0","endTime":"0","summary":"LUND, SE / ACCESS Newswire / April 29, 2025 / BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that the U.S. Food and Drug Administration  has granted Fast Track Designation to BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of adults with relapsed or refractory mycosis fungoides and Sézary syndrome, subtypes of cutaneous T-cell lymphoma . Fast Track Designation  is intended to facilitate the development and review of drugs that treat serious conditions.About Phase 1/2a studyDuring the first part of the Phase 1/2a study  the safety, tolerability, and potential signs of efficacy of BI-1808 as a single agent  and in combination with the anti-PD-1 therapy pembrolizumab  are evaluated in patients with advanced solid tumors and T-cell lymphoma. The efficacy of BI-1808 as single agent is currently explored in the Phase 2a part of the tria","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-receives-fda-fast-track-101500462.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4213","BK4161","FAST","SD","CR","PR","BK4139","BOVNF"],"gpt_icon":0},{"id":"2531229051","title":"BioInvent International AB: Interim Report January - March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531229051","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531229051?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:20","pubTimestamp":1745907600,"startTime":"0","endTime":"0","summary":"LUND, SE / ACCESS Newswire / April 29, 2025 / BioInvent International . \"The first quarter of 2025 was a highly productive period across clinical development, regulatory milestones, and strategic partnerships - positioning us for strong momentum through the remainder of the year.\"- Martin Welschof CEO of BioInvent. Phase 1 data of the company's second anti-TNFR2 antibody BI-1910 as monotherapy for the treatment of solid tumors. BioInvent achieved ISO 26000 Verification, highlighting commitment to ESG and transparency. Composition of matter patent for the lead anti-TNFR2 antibody BI-1808 granted in Japan. It also covers the use of the antibody in the treatment of cancer. About BioInventBioInvent International AB  is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-international-ab-interim-report-062000414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BOVNF","BK4135","BK4232","BK4598","LU0029874061.USD","BK4022","BK4590","R","AB","BK4139","LU0128526141.USD"],"gpt_icon":0},{"id":"2525248895","title":"BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2525248895","media":"ACCESS Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525248895?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:15","pubTimestamp":1744110900,"startTime":"0","endTime":"0","summary":"LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that it has earned a 1 million USD milestone payment, following Takeda's  initiation of Phase 3 clinical trial of mezagitamab , identified from BioInvent's proprietary n-CoDeR antibody library. The study is evaluating this potential best-in-class anti-CD83 monoclonal antibody for persistent or chronic primary immune thrombocytopenia .\"We are excited to see mezagitamab progress into Phase 3 trials, marking a significant step for Takeda and our n-CoDeR platform,\" said Martin Welschof, Chief Executive Officer of BioInvent. \"This milestone not only validates the consistent high quality of drug candidates identified from our n-CoDeR antibody library, but it also highlights the success of our out-licensing strategy and its ability to drive real-world impact t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-receives-milestone-payment-takeda-111500286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XOMA","BK4199","ITP","BOVNF","BK4139","BK4007","TAK"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BOVNF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-04-24","symbol":"BOVNF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1713931200000,"reportTimeType":"","actualEps":null},{"date":"2022-10-27","symbol":"BOVNF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1666857600000,"name":null,"time":"Pre-Market","dateTimestamp":1666843200000,"actualEps":null},{"date":"2022-08-25","symbol":"BOVNF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1661414400000,"name":null,"time":"Pre-Market","dateTimestamp":1661400000000,"actualEps":null},{"date":"2022-04-27","symbol":"BOVNF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1651046400000,"name":null,"time":"Pre-Market","dateTimestamp":1651032000000,"actualEps":null},{"market":"US","date":"2020-12-14","symbol":"BOVNF","defaultRemindTime":1607956200000,"type":"split","dateTimestamp":1607922000000,"forFactor":25,"toFactor":1,"ratio":25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BOVNF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BOVNF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1743480000000}}}